Wat betsjut "Dúdlik"?
It bist draacht de mutaasje net. It sil de sykte net ûntwikkelje en sil it net trochjaan.
Glanzmann Thrombasthenia (GT) in Great Pyrenees is a rare inherited blood disorder affecting platelet function, leading to excessive bleeding. DNA testing for GT in Great Pyrenees dogs helps breeders identify carriers and prevent passing this serious condition to puppies. Early detection through a simple genetic test ensures better health management and reduces the risk of life-threatening hemorrhages. Responsible breeders prioritize GT DNA testing to maintain the breed’s overall health and vitality. If you own or plan to breed Great Pyrenees, DNA testing for Glanzmann Thrombasthenia is essential for safe and ethical breeding practices. Stay informed and protect your dog’s well-being with reliable GT genetic testing.
Glanzmann Thrombasthenia (GT) is a rare inherited bleeding disorder found in Great Pyrenees dogs. It affects platelet function, leading to impaired blood clotting and increased risk of excessive bleeding. A DNA test can identify carriers and affected dogs, helping breeders make informed decisions. Early detection through genetic testing is crucial for managing the health of affected dogs. Responsible breeding practices can reduce the prevalence of GT in the Great Pyrenees population.
Dizze DNA-test is opnommen fanôf ús pakket Basic - en is ek diel fan 'e pakketten Basic, Standard, Advanced, Complete.
Besjoch DNA-testpakketten →Glanzmann Thrombasthenia (GT) is a rare inherited bleeding disorder that affects the ability of platelets to aggregate, leading to impaired blood clotting. This condition is particularly important to be aware of in Great Pyrenees, a breed known for its gentle and protective nature. GT is caused by a defect in the gene responsible for producing glycoprotein IIb/IIIa, which is crucial for platelet function. As a result, dogs affected by this condition may experience prolonged bleeding after injuries, surgical procedures, or even spontaneously without any apparent cause.
The clinical signs of Glanzmann Thrombasthenia can vary in severity among affected Great Pyrenees. Common symptoms include prolonged bleeding from cuts or wounds, excessive bruising, and in some cases, bleeding from the nose or gastrointestinal tract. Pet owners may also notice that their dog tires easily or shows signs of weakness, particularly after exertion. It is essential for owners to be vigilant and consult a veterinarian if any of these signs are observed, as timely intervention can be crucial for managing the condition.
Diagnosing Glanzmann Thrombasthenia typically involves a combination of clinical evaluation and specialized laboratory tests. A veterinarian will assess the dog's medical history, perform a physical examination, and may recommend blood tests to evaluate platelet function and count. These tests help identify abnormalities in the platelets that are characteristic of GT. Genetic testing is also available to confirm the diagnosis and identify carriers of the gene mutation, assisting breeders in making informed decisions.
While there is no cure for Glanzmann Thrombasthenia, management strategies can help mitigate the risks associated with the condition. The primary focus of treatment is to prevent bleeding episodes and address any that do occur. This may involve avoiding situations that could lead to injury, as well as close monitoring during surgical procedures. In some cases, blood transfusions or platelet concentrates may be necessary to manage severe bleeding. Additionally, veterinarians may recommend supportive care and regular check-ups to monitor the dog's health and platelet function over time.
Glanzmann Thrombasthenia is a significant health concern for Great Pyrenees and their owners. Understanding the nature of this condition, its symptoms, and management strategies can help improve the quality of life for affected dogs. Awareness and education are key in ensuring that Great Pyrenees with GT receive the appropriate care and attention they need to thrive.
It bist draacht de mutaasje net. It sil de sykte net ûntwikkelje en sil it net trochjaan.
Nee, it bist is oer it algemien sûn, mar kin de mutaasje oerjaan oan har neiteam.
It draacht twa mutearre eksimplaren. Klinyske tekens wurde ferwachte ôfhinklik fan de sykte. It moat net fokt wurde.
Guon sykten binne seks-keppele, sadat harren útdrukking fariearret ôfhinklik fan de bist syn seks.
This DNA test detects the mutation associated with Glanzmann Thrombasthenia In Great Pyrenees (GT-GP) in order to identify clear, carrier, or at-risk animals.
DNA-testen helpt fokkers om feiliger parings te plannen en it risiko te ferminderjen fan it oerdragen fan de mutaasje nei neiteam.
De erflike modus rapportearre foar dizze test is Autosomal Recessive.
This test analyses the mutation ITGA2B c.1360_1373dup.
Net needsaaklik. Ynterpretaasje hinget ôf fan it erflik patroan en de resultearjende genotyp.
Lipscomb D L, Bourne C, Boudreaux M K. Two genetic defects in alphaIIb are associated with type I Glanzmann's thrombasthenia in a Great Pyrenees dog: a 14-base insertion in exon 13 and a splicing defect of intron 13. Vet Pathol. 2000 Nov;37(6):581-8. doi: 10.1354/vp.37-6-581.
Jo privacy, jo kar
Wy brûke essensjele cookies om de webside út te fieren. Opsjonele cookies (lykas oanbieders fan ynbêde ynhâld) binne standert útskeakele en binne allinich ynskeakele as jo it iens binne. Jo kinne jo kar op elk momint feroarje mei de knop "Koekjes".
Fereaske foar kearnfunksjes en feiligens. Altyd ynskeakele.
Ferbetteret funksjes lykas foarkarbesparring of net-reklame-ynbêden.
Helpt ús sitegebrûk te begripen. Standert útskeakele.
Advertearje / folgjen oer siden (guon fideo / kaarten ynbêde). Standert útskeakele.